Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis.
Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis.
复制标题
DOI：
10.1590/abd1806-4841.20186803
复制
发表时间：
2018-07
影响因子：
1.7
通讯作者：
Shinjo SK
中科院分区：
文献类型：
--
作者：
Borges IBP;Silva MG;Shinjo SK
目前还没有关于巴西皮肌炎患者样本中抗黑色素瘤分化相关基因5（抗MDA-5）的频率和反应性的研究。分析巴西人群中的这种自身抗体。这是一项单中心横断面研究，在2000年至2016年期间对131例连续成人活动性疾病患者（109例皮肌炎和22例临床无肌病性皮肌炎）进行了评价。通过ELISA进行抗MDA-5自身抗体的分析。在皮肌炎和临床无肌病性皮肌炎患者中分别观察到14.7%和22.7%存在这种自身抗体。皮肌炎患者自身抗体与雷诺氏现象及甲周充血的相关性较低（P<0.05）。在临床上无肌病性皮肌炎中，这种自身抗体的存在与任何人口统计学、临床、实验室或影像学特征无统计学相关性。横断面研究设计不允许建立抗MDA-5自身抗体和各种研究变量之间的时间相关性。此外，未对患者进行肺功能检查。抗MDA-5自身抗体的频率与其他皮肌炎人群相当，但与文献中描述的反应性不同。此外，我们的临床无肌病性皮肌炎患者与文献中描述的患者之间存在表型变异。需要进一步的研究来证实目前的研究结果，并阐明这种自身抗体在巴西特发性炎性肌病患者中的反应性。
There have been no studies to date on the frequency and reactivity of aanti-melanoma differentiation-associated gene 5 (anti-MDA-5) in samples from the Brazilian population with dermatomyositis. To analyze this autoantibody in the Brazilian population. This was a single-center cross-sectional study in which 131 consecutive adult patients (109 dermatomyositis and 22 clinically amyopathic dermatomyositis) with active disease were evaluated from 2000 to 2016. Analysis of the anti-MDA-5 autoantibody was performed by ELISA. The presence of this autoantibody was observed in 14.7% and 22.7% of patients with dermatomyositis and clinically amyopathic dermatomyositis, respectively. In the case of dermatomyositis, the autoantibody was associated less frequently with Raynaud’s phenomenon and periungual hyperemia (P<0.05). In clinically amyopathic dermatomyositis, the presence of this autoantibody was not associated statistically with any demographic, clinical, laboratory, or imaging characteristics. The cross-sectional study design did not allow establishing a temporal correlation between anti-MDA-5 autoantibody and various study variables. In addition, pulmonary function tests were not performed in the patients. The frequency of anti-MDA-5 autoantibody was comparable to that of other populations with dermatomyositis, but with a different reactivity than described in the literature. In addition, there was a phenotypic variability between our patients with clinically amyopathic dermatomyositis and those described in the literature. Further studies are needed to confirm the current study’s findings and elucidate this autoantibody’s reactivity in Brazilians with idiopathic inflammatory myopathies.